Universal Biosensors Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Universal Biosensors Inc (UBI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Universal Biosensors Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 4M vs 92,970M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-25.0% annualized vs trailing 12 months), vs decelerating (-5.0%) for its tracked peer group.
- Growth: Universal Biosensors Inc generated -27.7% revenue growth year over year in Q2 2025, vs 8.7% for its competitors combined.
- Profitability: Its -547.1% net margin compares with 13.9% for the peer group.
- Peer revenue share: Universal Biosensors Inc accounted for 0.0% of combined revenue among its tracked peer group, down from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.05M compares with $0.40M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
UBI Sales vs. its Competitors, Q2 2025
Universal Biosensors Inc reported revenue contraction of 27.72 % year on year in Q2 2025, below its competitors' combined revenue growth of 8.71 %.
With a net margin of -547.12 %, Universal Biosensors Inc reported lower profitability than its competitors (13.93 %).
Universal Biosensors Inc generated 0.00 % of the combined sales of its peer group, down from 0.01 % a year earlier.
Universal Biosensors Inc vs. its Competitors, Q2 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Universal Biosensors Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Universal Biosensors Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Universal Biosensors Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Universal Biosensors Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 14.8% year over year, combined, vs -27.7% for Universal Biosensors Inc. Universal Biosensors Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Universal Biosensors Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Universal Biosensors Inc | No | No | No | Yes |
| Competitors combined (17) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
UBI Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Movano Inc | 282.9% | Outperformed |
| 2 | Tandem Diabetes Care Inc | 282.9% | Outperformed |
| 3 | Dexcom Inc | 282.9% | Outperformed |
| 4 | Medtronic Plc | 282.9% | Outperformed |
| 5 | Endra Life Sciences Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Universal Biosensors Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Universal Biosensors Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Universal Biosensors Inc |
- | 4.13 |
 Abbott Laboratories |
189,234.21 | 45,134.00 |
 Medtronic Plc |
124,680.40 | 37,542.00 |
 Dexcom Inc |
32,043.34 | 5,104.90 |
 Insulet Corporation |
10,643.99 | 3,053.40 |
 Modular Medical Inc |
9,650.04 | - |
| SUBTOTAL | 368,599.91 | 92,974.59 |
Sign in to see all competitors of Universal Biosensors Inc .
Sources: Universal Biosensors Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Universal Biosensors Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Universal Biosensors Inc's Competitors Named by the Company
Competitive relationships identified from Universal Biosensors Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Dexcom Inc | Company report | 85% |
| Gamer Pakistan Inc | Company report | 85% |
| Embecta Corp | Company report | 85% |
| Medtronic Plc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Glucotrack Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Universal Biosensors Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Universal Biosensors Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Universal Biosensors Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Abbott Laboratories | Diabetes Care 17.78 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Dexcom Inc | Reportable 100.00 % |
| Semler Scientific inc | Single reportable segment 100.00 % |
| Movano Inc | AI Platform and Services 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Universal Biosensors Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Universal Biosensors Inc | - | 47,453 | -143,978 |
| Abbott Laboratories | 189,234 | 392,470 | 54,574 |
| Medtronic Plc | 124,680 | 395,179 | 55,463 |
| Dexcom Inc | 32,043 | 459,901 | 89,432 |
| Insulet Corporation | 10,644 | 565,444 | 69,500 |
| Modular Medical Inc | 9,650 | - | -549,529 |
| PEERS TOTAL | 368,600 | 401,977 | 89,937 |
Sign in to see all peers for Universal Biosensors Inc .
Universal Biosensors Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Abbott Laboratories | Non-US 61.62 % |
| Medtronic Plc | United States 49.83 % |
| Dexcom Inc | United States 72.13 % |
| Insulet Corporation | United States 68.11 % |
| Tandem Diabetes Care Inc | United States 65.17 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Universal Biosensors Inc .
Universal Biosensors Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (320 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.27 % | 21.06 % (avg) | -20.8 pp |
| Operating Margin | -2.98 % | industry median | +0.5 pp |
| EBITDA Margin | -2.85 % | -4.07 % (avg) | +1.2 pp |
| Capital Intensity (Capex / Revenue) | 8.24 % | 6.78 % (avg) | +1.5 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Universal Biosensors Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | 76.03 % | - | - | - | -26.55 % | - | - |
| Operating Margin | -61.98 % | - | - | -260.28 % | - | - | - |
| Return on Invested Capital | -9.96 % | - | - | -20.55 % | -46.07 % | 10.06 % | -32.27 % |
| P/E | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Universal Biosensors Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 8.24 % vs industry average 6.78 % (see Profitability & Cost Structure above) |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments. Supplier power and buyer power are not assessed here -- see Universal Biosensors Inc's dedicated Suppliers and Customers pages for concentration data; threat of substitutes has no systematic data source in this system and is not estimated.
Universal Biosensors Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Universal Biosensors Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Universal Biosensors Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 10.3 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-25.0% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (35.30 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-5.0% annualized).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Universal Biosensors Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Universal Biosensors Inc | 2.26 | 3.70 | 0.02 |
| Abbott Laboratories | 0.47 | 1.60 | 0.35 |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Dexcom Inc | 0.46 | 1.82 | 0.46 |
| Insulet Corporation | - | 2.66 | 0.86 |
| Modular Medical Inc | 3.38 | 3.67 | - |
Sign in to see all peers for Universal Biosensors Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Universal Biosensors Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Universal Biosensors Inc | Q2 2025 | -27.7 % | - |
| Abbott Laboratories | Q1 2026 | +7.8 % | -18.7 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Dexcom Inc | Q3 2026 | +11.3 % | -3.1 % |
| Insulet Corporation | Q2 2026 | +23.5 % | +322.2 % |
| Modular Medical Inc | Q2 2026 | - | - |
| PEERS TOTAL | +10.6 % | +305.6 % |
Sign in to see all peers for Universal Biosensors Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Universal Biosensors Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Universal Biosensors Inc | Q2 2025 | +416.0 % | -67.2 % |
| Abbott Laboratories | Q1 2026 | +9.4 % | -17.6 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Dexcom Inc | Q3 2026 | +0.6 % | -34.3 % |
| Insulet Corporation | Q2 2026 | +21.4 % | +60.8 % |
| Modular Medical Inc | Q2 2026 | - | -26.3 % |
Sign in to see all peers for Universal Biosensors Inc .
Universal Biosensors Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Universal Biosensors Inc | - | - | - |
| Abbott Laboratories | 6.87% | 8.15% | 12.09% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Dexcom Inc | 15.47% | 18.92% | 36.56% |
| Insulet Corporation | 12.13% | 14.30% | 26.69% |
| Modular Medical Inc | - | - | - |
Sign in to see all peers for Universal Biosensors Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Universal Biosensors Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Universal Biosensors Inc | - | - |
| Abbott Laboratories | 30.17 | 4.19 |
| Medtronic Plc | 285.35 | 3.32 |
| Dexcom Inc | 32.90 | 6.28 |
| Insulet Corporation | 28.94 | 3.49 |
| Modular Medical Inc | - | - |
| PEERS AVERAGE | 17.73 | 3.96 |
Sign in to see all peers for Universal Biosensors Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.